



a**DLD1 Pyroptosis****DLD1 Apoptosis**

Fig.4 | The effect of inhibitors on PANoptosis induced by co-treatment of IFN- γ and TNF- α .



b**HCT116 Pyroptosis****HCT116 Apoptosis**

Fig.4 | The effect of inhibitors on PANoptosis induced by co-treatment of IFN- γ and TNF- α .


c

Fig.4 | The effect of inhibitors on PANoptosis induced by co-treatment of IFN- γ and TNF- α .




d**DLD1 Pyroptosis****HCT116 Pyroptosis**

Fig.4 | The effect of inhibitors on PANoptosis induced by co-treatment of IFN- γ and TNF- α .

d DLD1 Pyroptosis



HCT116 Pyroptosis





Fig.4 | The effect of inhibitors on PANoptosis induced by co-treatment of IFN- γ and TNF- α .

e

DLD1 Pyroptosis



HCT116 Pyroptosis




Fig.4 | The effect of inhibitors on PANoptosis induced by co-treatment of IFN- γ and TNF- α .

f



DLD1 Pyroptosis**HCT116 Pyroptosis**

Fig.4 | The effect of inhibitors on PANoptosis induced by co-treatment of IFN- γ and TNF- α .




a**b**

Fig.5 | Oligomerization of NT-GSDMD, NT-GSDME and p-MLKL triggers PANoptosis after co-treatment of IFN- γ + TNF- α .

Sensors of Cytoplasmic DNA fragments

a



b




Fig.6 | DNA sensors for DNA fragments in Cancer cells with dMMR are in the nucleus, not in the cytoplasm.



a**b**

Fig.7 | Hyperactivation of PANoptosis effective molecules by AIM2-ZBP1-RIPK1-RIPK3-ASC-CASP8-CASP1 signal pathway.


d

Fig.7 | Hyperactivation of PANoptosis effective molecules by AIM2-ZBP1-RIPK1-RIPK3-ASC-CASP8-CASP1 signal pathway.

a




Fig.10 | *Mlh1* knockout CT26 and CMT93 undergo natural hyperactivation of GSDMD, GSDME and p-MLKL.


b

Fig.10 | *Mlh1* knockout CT26 and CMT93 undergo natural hyperactivation of GSDMD, GSDME and p-MLKL.

C





Fig.10 | *Mlh1* knockout CT26 and CMT93 undergo natural hyperactivation of GSDMD, GSDME and p-MLKL.



C

Fig.10 | *Mlh1* knockout CT26 and CMT93 undergo natural hyperactivation of GSDMD, GSDME and p-MLKL.

d




Fig.10 | *Mlh1* knockout CT26 and CMT93 undergo natural hyperactivation of GSDMD, GSDME and p-MLKL.